SS
SABS icon

SBI Securities’s SAB Biotherapeutics SABS Stock Holding History

SBI Securities’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$187 – 4137
2025
Q4 		$187 Sell
50
-2
-4% -$7 ﹤0.01% 3233
2025
Q3 		$105 Buy
52
+2
+4% +$5 ﹤0.01% 3506
2025
Q2 		$88 Hold
50
– – ﹤0.01% 3577
2025
Q1 		$68 Buy
+50
New +$115 ﹤0.01% 3566

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SBI Securities's SABS Position: Q1 2026 in Review

SBI Securities sold out of SAB Biotherapeutics (SABS) in Q1 2026, closing a stake of 50 shares — an estimated $187 sold.

SBI Securities first reported a position in SABS in Q1 2025 and held it in 4 quarters. The position peaked at $187 in Q4 2025. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • SBI Securities reported no remaining SAB Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • SBI Securities sold 50 SAB Biotherapeutics shares in Q1 2026, an estimated $187.
  • SBI Securities first reported a position in SAB Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • SBI Securities's SAB Biotherapeutics position peaked at $187 in Q4 2025.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.